STAMPEDE: Front-Line Docetaxel Prolongs Survival in Metastatic Prostate Cancer

June 4, 2015
Nicholas James, MD

In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.

In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.

Related Content:

ASCO | Prostate Cancer